Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bimatoprost + timolol ocular insert
- Development stage
- Unknown
- Lead developer
- Allergan
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
The bimatoprost + timolol ocular insert is a sustained-release drug delivery system developed by ForSight Vision5 (later acquired by Allergan) for the treatment of open-angle glaucoma and ocular hypertension. The device is a non-invasive, preservative-free peri-ocular ring that rests in the conjunctival fornix, providing continuous elution of both active ingredients over several weeks. Bimatoprost, a prostaglandin analog, lowers intraocular pressure by increasing uveoscleral outflow through the activation of prostaglandin F receptors. Timolol, a non-selective beta-adrenergic antagonist, complements this effect by reducing the production of aqueous humor in the ciliary body. This combination approach aims to improve patient compliance by replacing daily eye drops with a long-acting insert.
- Other names
- Fixed Combination Bimatoprost/Timolol Ocular InsertHelios combination ringBimatoprost/Timolol Ring
02
Targets
ADRB1 (β1)PTGER (Prostaglandin E2 receptor)ADRB2 (β2)PTGFR (Prostaglandin F2 alpha receptor)
Beyond the preview
Go deeper on bimatoprost + timolol ocular insert.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bimatoprost + timolol ocular insert.